Literature DB >> 27402834

Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins.

Dario Venetz1, Danil Koovely2, Bruce Weder2, Dario Neri3.   

Abstract

The targeted assembly of antibody products upon antigen binding represents a novel strategy for the reconstitution of potent therapeutic activity at the site of disease, sparing healthy tissues. We demonstrate that interleukin-12, a heterodimeric pro-inflammatory cytokine consisting of the disulfide-linked p40 and p35 subunits, can be reconstituted by sequential reassembly of fusion proteins based on antibody fragments and interleukin-12 subunit mutants. Analysis of the immunostimulatory properties of interleukin-12 and its derivatives surprisingly revealed that the mutated p35 subunit partially retained the activity of the parental cytokine, whereas the p40 subunit alone was not able to stimulate T cells or natural killer cells. The concept of stepwise antibody-based reassembly of split cytokines could be useful for the development of other anticancer therapeutics with improved safety and tolerability.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  activity reconstitution; activity-on-demand; antibody; cancer; cytokine; immunotherapy; interleukin-12; pharmacology; split protein; tumor targeting

Mesh:

Substances:

Year:  2016        PMID: 27402834      PMCID: PMC5000063          DOI: 10.1074/jbc.M116.737734

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

Authors:  J P Leonard; M L Sherman; G L Fisher; L J Buchanan; G Larsen; M B Atkins; J A Sosman; J P Dutcher; N J Vogelzang; J L Ryan
Journal:  Blood       Date:  1997-10-01       Impact factor: 22.113

2.  High efficiency cell-specific targeting of cytokine activity.

Authors:  Geneviève Garcin; Franciane Paul; Markus Staufenbiel; Yann Bordat; José Van der Heyden; Stephan Wilmes; Guillaume Cartron; Florence Apparailly; Stefaan De Koker; Jacob Piehler; Jan Tavernier; Gilles Uzé
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

3.  Biopharmaceutical benchmarks 2014.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2014-10       Impact factor: 54.908

Review 4.  The role of interleukin-2 during homeostasis and activation of the immune system.

Authors:  Onur Boyman; Jonathan Sprent
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

5.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

6.  Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.

Authors:  Barbara Carnemolla; Laura Borsi; Enrica Balza; Patrizia Castellani; Raffaella Meazza; Alexander Berndt; Silvano Ferrini; Hartwig Kosmehl; Dario Neri; Luciano Zardi
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

7.  Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.

Authors:  Roberto Sommavilla; Nadine Pasche; Eveline Trachsel; Leonardo Giovannoni; Christoph Roesli; Alessandra Villa; Dario Neri; Manuela Kaspar
Journal:  Protein Eng Des Sel       Date:  2010-06-15       Impact factor: 1.650

Review 8.  Monoclonal antibody therapies for solid tumors.

Authors:  Dimiter V Tassev; Nai-Kong V Cheung
Journal:  Expert Opin Biol Ther       Date:  2009-03       Impact factor: 4.388

9.  Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

Authors:  Onur Boyman; Marek Kovar; Mark P Rubinstein; Charles D Surh; Jonathan Sprent
Journal:  Science       Date:  2006-02-16       Impact factor: 47.728

10.  Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

Authors:  Andrea Gallamini; Francesco Zaja; Caterina Patti; Atto Billio; Maria Rosaria Specchia; Alessandra Tucci; Alessandro Levis; Annunziata Manna; Vicenzo Secondo; Luigi Rigacci; Antonello Pinto; Emilio Iannitto; Valerio Zoli; Pierfederico Torchio; Stefano Pileri; Corrado Tarella
Journal:  Blood       Date:  2007-06-20       Impact factor: 22.113

View more
  7 in total

1.  An engineered 4-1BBL fusion protein with "activity on demand".

Authors:  Jacqueline Mock; Marco Stringhini; Alessandra Villa; Michael Weller; Tobias Weiss; Dario Neri
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-25       Impact factor: 11.205

Review 2.  Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.

Authors:  Dario Neri
Journal:  Cancer Immunol Res       Date:  2019-03       Impact factor: 11.151

Review 3.  Localized Interleukin-12 for Cancer Immunotherapy.

Authors:  Khue G Nguyen; Maura R Vrabel; Siena M Mantooth; Jared J Hopkins; Ethan S Wagner; Taylor A Gabaldon; David A Zaharoff
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

Review 4.  The present and future of immunocytokines for cancer treatment.

Authors:  Dennis Y Gout; Lotte S Groen; Marjolein van Egmond
Journal:  Cell Mol Life Sci       Date:  2022-09-06       Impact factor: 9.207

5.  Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment.

Authors:  Jiezuan Yang; Renyong Guo; Dong Yan; Haifeng Lu; Hua Zhang; Ping Ye; Linfeng Jin; Hongyan Diao; Lanjuan Li
Journal:  Front Cell Infect Microbiol       Date:  2020-07-24       Impact factor: 5.293

6.  A universal reporter cell line for bioactivity evaluation of engineered cytokine products.

Authors:  Jacqueline Mock; Christian Pellegrino; Dario Neri
Journal:  Sci Rep       Date:  2020-02-24       Impact factor: 4.379

Review 7.  Utilizing Immunocytokines for Cancer Therapy.

Authors:  Erin Runbeck; Silvia Crescioli; Sophia N Karagiannis; Sophie Papa
Journal:  Antibodies (Basel)       Date:  2021-03-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.